OncRef

Clinical Trial: NCT03728972

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-10-21

Study Overview

Brief Summary

The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.

Official Title

Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type

Conditions

NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Intervention / Treatment

  • Drug: Pembrolizumab

Other Study ID Numbers

  • 18-393

Start Date (Actual)

2018-11-09

Primary Completion Date (Actual)

2025-06-15

Study Completion Date (Estimated)

2026-11

Enrollment (Actual)

19

Study Type

Interventional

Phase

Phase 2